Blockbuster weight loss drugs can help treat ailments as disparate as addiction, blood clotting, and dementia – but they also come with risks that might give some patients pause, a landmark new study has found. The analysis used data from more than two ...

Unlike subcutaneous fat that lies just beneath our skin, visceral fat accumulates around our internal abdominal organs, including the liver, pancreas and intestines. This type of fat is associated with a number of negative health outcomes,

Ozempic and Wegovy are being linked to surprising effects on overall health. A new study finds these drugs may improve heart health, reduce infections, lower substance abuse risks, and even decrease the chance of dementia.

One recent analysis found that, over the course of three years, people taking semaglutide (the compound in Ozempic and the weight loss drug Wegovy) were about 40 to 70 percent less likely to be diagnosed with Alzheimer’s disease compared with people on other diabetes medications.

Research shows that GLP-1 receptor agonists like Ozempic can help you drop weight, manage diabetes ... your risk of developing a host of different health issues, including dementia. Of course, it isn't all positive. The scientists also found that these ...

News research shows GLP-1 medications may help treat a wide range of conditions, from addiction and dementia to heart disease and psychotic disorders.

A new study compares the benefits and risks of taking GLP-1 medications for weight loss, including risks of dementia, addiction, heart disease, and gastrointestinal problems, among others.

Popular GLP-1 medications approved for weight loss, diabetes, and heart disease may have untapped potential to reduce the risks of substance abuse disorders, psychosis, infections, some kinds of cancer and dementia,

Over 2 million people were included in new research to test these drugs against 175 different health outcomes.

Vaccines, antibiotics, antiviral medications and anti-inflammatory drugs are all associated with a reduced risk of dementia, researchers reported in a study published Tuesday in the journal Alzheimer's and Dementia: Translational Research & Clinical Interventions .

Research shows that people who take these weight-loss medications may have a lower risk of dementia and numerous other health conditions.

A recent study from Karolinska Institutet suggests that a type of diabetes medication called GLP-1 agonists could reduce the risk of dementia in people with type 2 diabetes. The study, published in eClinicalMedicine,